Chapter

In-stent restenosis in the drug-eluting stent era

Adriano Caixeta, Philippe Généreux, George Dangas and Roxana Mehran

in Oxford Textbook of Interventional Cardiology

Published on behalf of Oxford University Press

ISBN: 9780199569083
Published online July 2011 | e-ISBN: 9780199697816 | DOI: http://dx.doi.org/10.1093/med/9780199569083.003.028

Series: Oxford Textbooks

In-stent restenosis in the drug-eluting stent era

Show Summary Details

Preview

For the last two decades, restenosis has been considered the most significant problem in interventional cardiology. Drug-eluting stents (DES) have reduced rates of restenosis and target lesion revascularization (TLR) by 50–90% compared with bare-metal stents (BMS) across all lesion and patient subsets. However, a small number of patients have in-stent restenosis (ISR) after DES treatment. DES efficacy has been limited by suboptimal polymer biocompatibility, suitability of pharmacological agents, suboptimal in vivo pharmacokinetic properties, and local drug resistance and toxicity. The first two DES (sirolimus-eluting stents [SES] and paclitaxel- eluting stents [PES]) have the longest clinical follow- up, whereas the zotarolimus-eluting stents [ZES], everolimus-eluting stents [EES], and biolimus-eluting stents [BES] have only recently been introduced in daily practice. Although the low frequency of ISR events with DES makes it difficult to fully investigate this syndrome, many studies have been conducted or are ongoing to find the mechanism, incidence, predictors, and optimal treatment of DES restenosis. This review discusses the data relevant to DES restenosis and the perspective on the current treatment of this condition.

Chapter.  9631 words.  Illustrated.

Subjects: Radiology ; Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.